Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.790
-0.030 (-1.65%)
At close: Nov 20, 2024, 4:00 PM
1.808
+0.018 (1.01%)
After-hours: Nov 20, 2024, 6:39 PM EST
Akebia Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 169.88 | 194.62 | 292.48 | 211.65 | 294.64 | 335 | Upgrade
|
| Revenue Growth (YoY) | -12.53% | -33.46% | 38.19% | -28.17% | -12.05% | 61.26% | Upgrade
|
| Cost of Revenue | 26.95 | 39.76 | 22.5 | 81.49 | 63.96 | 105.35 | Upgrade
|
| Gross Profit | 142.93 | 154.86 | 269.99 | 130.16 | 230.68 | 229.65 | Upgrade
|
| Selling, General & Admin | 104.31 | 100.23 | 138.6 | 174.14 | 154.1 | 149.46 | Upgrade
|
| Research & Development | 35.73 | 63.08 | 129.99 | 147.85 | 218.49 | 322.97 | Upgrade
|
| Operating Expenses | 176.08 | 199.35 | 304.63 | 358.03 | 405.2 | 508.83 | Upgrade
|
| Operating Income | -33.15 | -44.5 | -34.64 | -227.88 | -174.52 | -279.18 | Upgrade
|
| Interest Expense | -12.73 | -6.03 | -15.69 | -20.02 | -8.92 | -0.03 | Upgrade
|
| Interest & Investment Income | - | - | - | 0.07 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 2.04 | 0.89 | 3.15 | 2.41 | 1.86 | -0.79 | Upgrade
|
| EBT Excluding Unusual Items | -43.84 | -49.64 | -47.18 | -245.42 | -181.58 | -280 | Upgrade
|
| Merger & Restructuring Charges | -0.06 | -0.18 | -15.93 | -21.58 | -68.24 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 0.02 | 0.05 | 0.82 | Upgrade
|
| Asset Writedown | -1.58 | -1.58 | -30.24 | -15.05 | -135.07 | -7.11 | Upgrade
|
| Other Unusual Items | -0.52 | -0.52 | -0.87 | - | - | - | Upgrade
|
| Pretax Income | -45.99 | -51.93 | -94.23 | -282.02 | -384.84 | -286.29 | Upgrade
|
| Income Tax Expense | - | - | - | - | - | -6.63 | Upgrade
|
| Net Income | -45.99 | -51.93 | -94.23 | -282.02 | -384.84 | -279.66 | Upgrade
|
| Net Income to Common | -45.99 | -51.93 | -94.23 | -282.02 | -384.84 | -279.66 | Upgrade
|
| Shares Outstanding (Basic) | 204 | 187 | 183 | 166 | 138 | 118 | Upgrade
|
| Shares Outstanding (Diluted) | 204 | 187 | 183 | 166 | 138 | 118 | Upgrade
|
| Shares Change (YoY) | 9.55% | 2.56% | 10.14% | 19.85% | 16.95% | 104.00% | Upgrade
|
| EPS (Basic) | -0.23 | -0.28 | -0.52 | -1.70 | -2.78 | -2.36 | Upgrade
|
| EPS (Diluted) | -0.23 | -0.28 | -0.52 | -1.70 | -2.78 | -2.36 | Upgrade
|
| Free Cash Flow | -38.53 | -23.38 | -73.27 | -253.02 | -110.71 | -264.1 | Upgrade
|
| Free Cash Flow Per Share | -0.19 | -0.12 | -0.40 | -1.52 | -0.80 | -2.23 | Upgrade
|
| Gross Margin | 84.13% | 79.57% | 92.31% | 61.50% | 78.29% | 68.55% | Upgrade
|
| Operating Margin | -19.52% | -22.86% | -11.84% | -107.67% | -59.23% | -83.34% | Upgrade
|
| Profit Margin | -27.07% | -26.68% | -32.22% | -133.25% | -130.61% | -83.48% | Upgrade
|
| Free Cash Flow Margin | -22.68% | -12.02% | -25.05% | -119.55% | -37.57% | -78.83% | Upgrade
|
| EBITDA | 4.41 | -6.87 | 3.06 | -189.91 | -139.83 | -240.53 | Upgrade
|
| EBITDA Margin | 2.60% | -3.53% | 1.04% | -89.73% | -47.46% | -71.80% | Upgrade
|
| D&A For EBITDA | 37.56 | 37.63 | 37.7 | 37.97 | 34.69 | 38.65 | Upgrade
|
| EBIT | -33.15 | -44.5 | -34.64 | -227.88 | -174.52 | -279.18 | Upgrade
|
| EBIT Margin | -19.52% | -22.86% | -11.84% | -107.67% | -59.23% | -83.34% | Upgrade
|
| Revenue as Reported | 169.88 | 194.62 | 292.48 | 211.65 | 294.64 | 335 | Upgrade
|
| Advertising Expenses | - | 1 | 6.7 | 8.2 | 5 | 6 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.